Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Trojano

Showing results (251-260 of 342) with videos related to

Pageof 35
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 3, 2020
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS studySandra Vukusic, Iuliana Ionescu, Catherine Cornu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|December 31, 2013
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Marco Capobianco, Maria Pia Amato, et al.
Annals of Neurology|February 12, 2022
Comparing Natural History of Early and Late Onset Pediatric Multiple SclerosisErmelinda De Meo, Massimo Filippi, Maria Trojano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 14, 2019
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MSCaroline Lavie, Fabien Rollot, Françoise Durand-Dubief, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 23, 2023
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiersLars Forsberg, Tim Spelman, Pernilla Klyve, et al.
Plos One|November 8, 2012
Geographical variations in sex ratio trends over time in multiple sclerosisMaria Trojano, Guglielmo Lucchese, Giusi Graziano, et al.
Journal of the Neurological Sciences|April 18, 2012
Increasing age at disability milestones among MS patients in the MSBase RegistryIlya Kister, Eric Chamot, Gary Cutter, et al.
Annals of Clinical and Translational Neurology|July 9, 2021
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and FranceMaria Pia Sormani, Marco Salvetti, Pierre Labauge, et al.
Annals of Clinical and Translational Neurology|July 6, 2024
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
Pageof 35

Showing results (251-260 of 342) with videos related to

Sort By:
Pageof 35
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 3, 2020
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS studySandra Vukusic, Iuliana Ionescu, Catherine Cornu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|December 31, 2013
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Marco Capobianco, Maria Pia Amato, et al.
Annals of Neurology|February 12, 2022
Comparing Natural History of Early and Late Onset Pediatric Multiple SclerosisErmelinda De Meo, Massimo Filippi, Maria Trojano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 14, 2019
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MSCaroline Lavie, Fabien Rollot, Françoise Durand-Dubief, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 23, 2023
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiersLars Forsberg, Tim Spelman, Pernilla Klyve, et al.
Plos One|November 8, 2012
Geographical variations in sex ratio trends over time in multiple sclerosisMaria Trojano, Guglielmo Lucchese, Giusi Graziano, et al.
Journal of the Neurological Sciences|April 18, 2012
Increasing age at disability milestones among MS patients in the MSBase RegistryIlya Kister, Eric Chamot, Gary Cutter, et al.
Annals of Clinical and Translational Neurology|July 9, 2021
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and FranceMaria Pia Sormani, Marco Salvetti, Pierre Labauge, et al.
Annals of Clinical and Translational Neurology|July 6, 2024
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
Pageof 35